Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24294920 | 0.80 | MOGAT2 (0.46) | MCHR1CARM1PRMT6 | |
| SCHEMBL22526350 | 0.79 | RORC (0.45) | MCHR1ALDH1A1RORCTSHRKMT2A | |
| SCHEMBL22296950 | 0.79 | HRH4 (0.52) | MCHR1CARM1PRMT6 | |
| SCHEMBL8251557 | 0.79 | RORC (0.56) | MCHR1RORC | |
| SCHEMBL23844240 | 0.79 | HRH3 (0.44) | ALDH1A1KMT2A | |
| SCHEMBL19368254 | 0.79 | NOTUM (0.51) | ALDH1A1TSHRKMT2A | |
| SCHEMBL23844510 | 0.78 | NOTUM (0.50) | ALDH1A1 | |
| SCHEMBL22849709 | 0.78 | ALDH1A1 (0.43) | MCHR1ALDH1A1RORCTSHRCARM1 | |
| SCHEMBL22856358 | 0.77 | MCHR1 (0.42) | MCHR1ALDH1A1RORC | |
| SCHEMBL23806804 | 0.77 | ALDH1A1 (0.40) | MCHR1ALDH1A1RORCTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | MCHR1 3929/4885ALDH1A1 4421/4885RORC 1704/4885 |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | MCHR1 3929/4885ALDH1A1 4421/4885RORC 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.